Abstract | PURPOSE: Oral oncolytics are becoming increasingly utilized for cancer treatment, but the frequency of off-label oral oncolytic use is not well described. The extent of off-label oral oncolytic use is a concern because the clinical benefits of such use to patients may not outweigh adverse health outcomes or cost concerns. METHODS: Prescription data for January 2011 through November 2013 from the St. Lukes Mountain States Tumor Institute (MSTI) Oral Chemotherapy program (OCP) was retrospectively analyzed. Use was classified as "on-label" if the cancer site, stage, and line of therapy met the FDA-approved indication. All other uses were classified as "off- label." Off-label use was further evaluated by whether it conformed to and was supported by National Comprehensive Cancer Network (NCCN) guideline recommendations. RESULTS: CONCLUSION: Oral chemotherapies are more often used on label than off label in current practice at our community cancer center. The majority of off-label use of oral oncolytics in this study was supported by NCCN guideline recommendations.
|
Authors | Joseph A Kalis, Simon J Pence, Robert S Mancini, Dan S Zuckerman, Joseph R Ineck |
Journal | Journal of oncology practice
(J Oncol Pract)
Vol. 11
Issue 2
Pg. e139-43
(Mar 2015)
ISSN: 1935-469X [Electronic] United States |
PMID | 25604593
(Publication Type: Journal Article)
|
Copyright | Copyright © 2015 by American Society of Clinical Oncology. |
Chemical References |
|
Topics |
- Administration, Oral
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Cancer Care Facilities
(statistics & numerical data)
- Humans
- Neoplasms
(drug therapy)
- Off-Label Use
(statistics & numerical data)
|